Cargando…

Immunoscore: a new possible approach for melanoma classification

Detalles Bibliográficos
Autores principales:	Capone, Mariaelena, Madonna, Gabriele, Sebastiao, Noemi, Bird , Jean, Ayala, Fabrizio, Caracò, Corrado, Ciliberto, Gennaro, La Fleur, Bonnie, Mozzillo, Nicola, Botti, Gerardo, Tubbs, Alisa, Ascierto, Paolo Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4292402/ http://dx.doi.org/10.1186/2051-1426-2-S3-P193

Ejemplares similares

MISIPI study: Melanoma ImmunoScore evaluation in patients treated with IPIlimumab
por: Bifulco, Carlo, et al.
Publicado: (2014)

The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment
por: Ascierto, Paolo A, et al.
Publicado: (2013)

Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015
por: Galon, J., et al.
Publicado: (2016)

Use of neoadjuvant electrochemotherapy to treat a large metastatic lesion of the cheek in a patient with melanoma
por: Mozzillo, Nicola, et al.
Publicado: (2012)

Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma
por: Colombino, Maria, et al.
Publicado: (2013)

Resection in the popliteal fossa for metastatic melanoma
por: Marone, Ugo, et al.
Publicado: (2007)

Superficial and deep lymph node dissection for stage III cutaneous melanoma: clinical outcome and prognostic factors
por: Mozzillo, Nicola, et al.
Publicado: (2013)

Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas
por: Manca, Antonella, et al.
Publicado: (2015)

Automatic discovery of image-based signatures for ipilimumab response prediction in malignant melanoma
por: Harder, Nathalie, et al.
Publicado: (2019)

Long-lasting response to electrochemotherapy in melanoma patients with cutaneous metastasis
por: Caracò, Corrado, et al.
Publicado: (2013)

Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy
por: Mozzillo, Nicola, et al.
Publicado: (2015)

Could asymptomatic carriers spread the SARS-CoV-2 infection? Experience from the Italian second wave
por: Atripaldi, Luigi, et al.
Publicado: (2021)

Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab
por: Capone, Mariaelena, et al.
Publicado: (2018)

ErbB3 Phosphorylation as Central Event in Adaptive Resistance to Targeted Therapy in Metastatic Melanoma: Early Detection in CTCs during Therapy and Insights into Regulation by Autocrine Neuregulin
por: Ruggiero, Ciro Francesco, et al.
Publicado: (2019)

Long-term response after electrochemotherapy in patients with relapsed or refractory cutaneous melanoma
por: Mozzillo, Nicola, et al.
Publicado: (2014)

Main roads to melanoma
por: Palmieri, Giuseppe, et al.
Publicado: (2009)

The role of spectrophotometry in the diagnosis of melanoma
por: Ascierto, Paolo A, et al.
Publicado: (2010)

Assessment of germline and somatic alterations in main candidate genes among patients with multiple primary melanoma
por: Colombino, Maria, et al.
Publicado: (2014)

Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November–2 December, 2017, Naples, Italy)
por: Ascierto, Paolo A., et al.
Publicado: (2018)

Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-α 2b treatment
por: Ascierto, Paolo A, et al.
Publicado: (2010)

AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment
por: Caputo, Emilia, et al.
Publicado: (2014)

AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment
por: Caputo, Emilia, et al.
Publicado: (2015)

Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab
por: Morello, Silvana, et al.
Publicado: (2017)

Dendritic cell-derived exosomes (Dex) are potential biomarkers of response to Ipilimumab in metastatic melanoma
por: Stucci, Stefania, et al.
Publicado: (2015)

Discrepant alterations in main candidate genes among multiple primary melanomas
por: Colombino, Maria, et al.
Publicado: (2014)

The Ratio of GrzB(+) − FoxP3(+) over CD3(+) T Cells as a Potential Predictor of Response to Nivolumab in Patients with Metastatic Melanoma
por: Scognamiglio, Giosuè, et al.
Publicado: (2021)

Tumor biobanks in translational medicine
por: Botti, Gerardo, et al.
Publicado: (2012)

Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations
por: Gentilcore, Giusy, et al.
Publicado: (2013)

Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy
por: Grimaldi, Antonio M, et al.
Publicado: (2014)

Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours
por: Galon, Jérôme, et al.
Publicado: (2014)

Analysis of T and NK cells immune response in Ipilimumab treated Melanoma patients
por: Tallerico, Rossana, et al.
Publicado: (2015)

Reverse transcriptase inhibition potentiates target therapy in BRAF-mutant melanomas: effects on cell proliferation, apoptosis, DNA-damage, ROS induction and mitochondrial membrane depolarization
por: Fattore, Luigi, et al.
Publicado: (2020)

Correction to: New paradigm for stage III melanoma: from surgery to adjuvant treatment
por: Ascierto, Paolo Antonio, et al.
Publicado: (2019)

Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma
por: Daponte, Antonio, et al.
Publicado: (2013)

Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations
por: Ascierto, Paolo A., et al.
Publicado: (2019)

Vitiligo-specific soluble biomarkers as early indicators of response to immune checkpoint inhibitors in metastatic melanoma patients
por: Carbone, Maria Luigia, et al.
Publicado: (2022)

A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation
por: Simeone, Ester, et al.
Publicado: (2021)

Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents
por: Turiello, Roberta, et al.
Publicado: (2022)

Correlation between immune-related adverse events and response to pembrolizumab in advanced melanoma patients
por: Grimaldi, Antonio Maria, et al.
Publicado: (2015)

Identification of a miRNA-based non-invasive predictive biomarker of response to target therapy in BRAF-mutant melanoma
por: Ruggiero, Ciro Francesco, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vk126l6erm71dpsl1einkfn7ek